India / Phase III human trial of Oxford COVID-19 vaccine begins in Pune

The Phase III clinical trial of the Oxford COVID-19 vaccine, being manufactured by Serum Institute of India (SII), began at the state-run Sassoon General Hospital in Pune on Monday. "We will administer [the vaccine] to 150 to 200 volunteers," hospital Dean Muralidhar Tambe said. Earlier, Phase II trials were conducted at the Bharati Vidyapeeth Medical College and KEM Hospital.

AIR : Sep 22, 2020, 09:26 AM

Pune: The phase-III human clinical trial of the COVID-19 vaccine being developed by Oxford University, and manufactured by the Serum Institute of India- SII, began today at the state-run Sassoon General Hospital in Pune.

According to the dean of Sasoon Hospital, the dose of the Vaccine is to be administered to 150 to 200 volunteers.

Under phase-II, trials had been conducted at the Bharti Vidyapeeth Medical College and also KEM Hospital in the city.

The SII has partnered with British-Swedish pharma company AstraZeneca for manufacturing the COVID-19 vaccine candidate, being developed by the University of Oxford.

Earlier this month, the SII had paused the clinical trials of the vaccine candidate in the country.

The Drugs Controller General of India (DCGI) had on September 11 directed the SII to suspend any new recruitment in the phase-II and III clinical trial of the vaccine till further orders after AstraZeneca paused the trials in other countries because of "an unexplained illness" in a participant in the study.

However, on September 15, the DCGI gave permission to the SII to resume clinical trial of the vaccine.